Angiotensin II receptor blockers and cardiorenal risk management: Irbesartan status
The article tells about the role of angiotensin II receptor blockers in risk management of cardiovascular and renal complications in diabetes mellitus. The results of clinical trials of Irbesartan (Aprovel®) are demonstrated.
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2013-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1100 |